Cell-permeable blocking peptide targeting PIAS1-GSK3β interaction mitigates tauopathy and cognitive deficits in Alzheimer's disease models.
Background
Alzheimer's disease (AD) is a devastating neurodegenerative disorder marked by progressive cognitive decline, largely driven by the accumulation of pathological Tau protein (tauopathy). While SUMOylation is known to influence tauopathy, the precise mechanisms linking specific E3 ligases to Tau hyperphosphorylation and aggregation remain poorly understood. Current AD treatments primarily manage symptoms, highlighting an urgent need for therapies that target core pathological processes like tauopathy. This study identifies a critical SUMO E3 ligase, PIAS1, and its role in exacerbating tau pathology via GSK3β activation, presenting a novel therapeutic target.
Study Design
Researchers employed a bimolecular fluorescence complementation (BiFC) assay to monitor Tau-Tau aggregation and screen for SUMO E3 ligases, identifying PIAS1. Genetic analysis of the UK Biobank cohort investigated associations between PIAS1 gene polymorphisms and AD risk. PIAS1 expression was assessed in postmortem AD brains, aging PS19 tauopathy mice, aged wild-type mice, aged lemurs, and neurons stimulated with amyloid-beta or lipopolysaccharide. Viral-mediated modulation of PIAS1 was performed in vivo to study its impact on Tau pathology. Finally, a cell-permeable blocking peptide, designed to disrupt the PIAS1-GSK3β interaction, was administered to both in vitro and in vivo models to evaluate its therapeutic potential against tauopathy and neurodegeneration.
Results
Genetic analysis of the UK Biobank cohort revealed that single nucleotide polymorphisms in the PIAS1 gene (rs8036154 and rs112677781) are significantly associated with a reduced risk of Alzheimer's disease. Consistent with this, PIAS1 expression was found to be upregulated in postmortem AD brains, aging PS19 tauopathy mice, aged wild-type mice, aged lemurs, and neurons stimulated with amyloid-beta or lipopolysaccharide. Viral-mediated PIAS1 modulation in vivo demonstrated that PIAS1 promotes Tau hyperphosphorylation and aggregation, thereby exacerbating synaptic dysfunction and cognitive deficits. Mechanistically, PIAS1 directly interacts with and mediates the SUMOylation of glycogen synthase kinase 3 beta (GSK3β) at lysine residues 183 and 271. This specific SUMOylation reduces inhibitory phosphorylation at Ser9, consequently enhancing GSK3β-mediated Tau kinase activity. Importantly, the engineered cell-permeable blocking peptide effectively suppressed GSK3β activation and mitigated tauopathy and neurodegeneration in both in vitro and in vivo models.
The PIAS1-mediated SUMOylation of GSK3β at Lys183 and Lys271 is a critical step that reduces inhibitory Ser9 phosphorylation, thereby boosting GSK3β's Tau kinase activity and driving pathology.
Key Findings
- PIAS1 gene SNPs (rs8036154, rs112677781) are significantly associated with reduced AD risk in the UK Biobank cohort.
- PIAS1 expression is upregulated in postmortem AD brains, aging tauopathy mice, and Aβ/LPS-stimulated neurons.
- PIAS1 promotes Tau hyperphosphorylation and aggregation, exacerbating synaptic dysfunction and cognitive deficits.
- PIAS1 directly mediates SUMOylation of GSK3β at Lys183 and Lys271, reducing inhibitory Ser9 phosphorylation.
- A cell-permeable blocking peptide disrupts PIAS1-GSK3β interaction, suppressing GSK3β activation and mitigating tauopathy.
Why It Matters
This research uncovers a novel PIAS1-GSK3β signaling axis as a key driver of tauopathy in Alzheimer's disease, offering a new, targeted therapeutic strategy. For peptide users and biohackers, the development of a cell-permeable blocking peptide that disrupts this interaction represents a significant advance, demonstrating that specific protein-protein interactions can be therapeutically modulated to mitigate neurodegeneration. This finding suggests a potential pathway for developing peptide-based interventions that directly address the underlying pathology of AD, rather than just managing symptoms. While still in preclinical stages, the success of the blocking peptide in vivo provides a strong rationale for further development towards a usable clinical protocol, potentially offering a novel approach to prevent or slow the progression of tauopathies. Targeting PIAS1-GSK3β interaction with a peptide could offer a precision medicine approach to AD.
alzheimers-disease
tauopathy
pias1
gsk3b
sumoylation
neurodegeneration